All In MedTech

Device Trial Radar · NCT04056715

Extended ECG Monitoring in HCM Patients

Extended Ambulatory Monitoring With iRhythm Zio XT Improves Care of Patients With Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

250

Actual

Start

Jan 14, 2020

Primary completion

Apr 18, 2022

Study completion Apr 18, 2022

Sponsor

Lead sponsor
iRhythm Technologies, Inc.Public (IRTC)
Sponsor type
Industry
First posted
Aug 14, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour monitoring.

Conditions

  • Hypertrophic Cardiomyopathy
  • Nonsustained Ventricular Tachycardia
  • Ventricular Tachycardia
  • Atrial Fibrillation
  • Arrhythmia

Interventions

  • Zio XTDevice

    ambulatory cardiac monitoring device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of nsVT runs through 14 days of ambulatory cardiac monitoring, as compared to the first 48 hours.Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.